Atossa appoints Greg Weaver as CFO, succeeding Kyle Guse effective June 1, 2023

ATOSSA THERAPEUTICS, INC.

Greg Weaver appointed EVP and CFO effective June 1, 2023, succeeding Kyle Guse who ceased as of May 26, 2023.
Weaver receives $450K base salary, 45% target bonus, $125K sign-on, and 2.6M stock options vesting over 4 years.
Weaver previously served as CFO of BioIntelliSense, Atai Life Sciences, and Eloxx Pharmaceuticals; also a director since 2013.
Guse will receive severance benefits per his employment agreement upon termination without cause.
Weaver's severance includes 6 months salary/benefits, or 12 months with equity acceleration upon change of control.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kyle Guse

General Counsel and Chief Financial Officer

ATOS · ATOSSA THERAPEUTICS, INC.

Effective: 2023-05-26
Successor: Greg Weaver
Filed: June 1, 2023, 7:59 PM ET

Mr. Weaver succeeds Kyle Guse, who ceased to serve as the Company’s General Counsel and Chief Financial Officer as of May 26, 2023.

Appointed

Greg Weaver

Executive Vice President and Chief Financial Officer

ATOS · ATOSSA THERAPEUTICS, INC.

Effective: 2023-06-01
Filed: June 1, 2023, 7:59 PM ET

Effective as of June 1, 2023 (the “Effective Date”), Atossa Therapeutics, Inc. (the “Company”) appointed Greg Weaver as the Company’s Executive Vice President and Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kyle Guse departed as General Counsel and Chief Financial Officer at ATOSSA THERAPEUTICS, INC..

Action: ceased to serve
Role: General Counsel and Chief Financial Officer

Exact text from the filing

Mr. Weaver succeeds Kyle Guse, who ceased to serve as the Company’s General Counsel and Chief Financial Officer as of May 26, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Greg Weaver was appointed as Executive Vice President and Chief Financial Officer at ATOSSA THERAPEUTICS, INC..

Action: appointed
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

Effective as of June 1, 2023 (the “Effective Date”), Atossa Therapeutics, Inc. (the “Company”) appointed Greg Weaver as the Company’s Executive Vice President and Chief Financial Officer.

View on SEC.gov

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-016319

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.